Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott J. Antonia, José A. López-Martin, Johanna Bendell, Patrick A. Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, M. Catherine Pietanza, Dung T. Le, Filippo de Braud, Michael A. Morse, Paolo A. Ascierto, Leora Horn, Asim Amin, Rathi N. Pillai, Jeffry Evans, Ian Chau, Petri Bono, Akin Atmaca, Padmanee SharmaChristopher T. Harbison, Chen Sheng Lin, Olaf Christensen, Emiliano Calvo

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences